Neurological adverse event after administration of the hepatitis A vaccine

2003 ◽  
Vol 115 (7) ◽  
pp. 587 ◽  
Author(s):  
David L. George ◽  
James G. Benonis
Keyword(s):  
Adverse Event ◽  
Hepatitis A ◽  
Neurological Adverse Event

scholarly journals Tardive Akathisia in an Adult on Long Term Metoclopramide

2021 ◽  
Vol 5 (4) ◽  
pp. CR1-CR3
Author(s):  
Subhshankar Prassad ◽  
Ron Meadows ◽  
Narayan Kamate
Keyword(s):  
Health Care ◽  
Adverse Event ◽  
Case Report ◽  
Health Care Professionals ◽  
Delayed Gastric Emptying ◽  
Drug Reactions ◽  
Loss Of Appetite ◽  
Tardive Akathisia ◽  
Neurological Adverse Event

Metoclopramide is prescribed to subjects dealing with gastrointestinal issues like delayed gastric emptying, nausea, vomiting or loss of appetite. It is also used to treat chemotherapy and surgery related nausea and vomiting.  Although it is very effective in targeting stomach related illnesses, severe adverse drug reactions can occur in those who take metoclopramide.  This case report describes a 32-year-old female who suffered from tardive akathisia while being treated with long-term metoclopramide. Long term exposure to causative medication leads to evolution of Tardive akathisia and this can stay for a lifetime. It is important to restrict the exposure duration of triggering drug. Health care professionals and patients should be well aware of this neurological adverse event of metoclopramide.

An Overview of Chemotherapy-Induced Peripheral Neuropathy

2008 ◽  
Vol 21 (2) ◽  
pp. 138-145 ◽  
Author(s):  
Jose R. Murillo ◽  
James E. Cox ◽  
Michael S. Oholendt
Keyword(s):  
Adverse Event ◽  
Peripheral Neuropathy ◽  
Positive Impact ◽  
Chemotherapeutic Agents ◽  
Patient Specific ◽  
Drug Discontinuation ◽  
Neurologic Complication ◽  
Patients With Cancer ◽  
Neurological Adverse Event

Peripheral neuropathy remains a major limitation of chemotherapeutic agents used in cancer treatment. This neurologic complication from chemotherapy occurs frequently and can be debilitating. Although difficult to predict, both chemotherapeutic and patient-specific risk factors may contribute to this adverse event. Symptoms of peripheral neuropathy may appear acutely after treatment or persist chronically upon drug discontinuation. The taxanes, vinca alkaloids, and immunomodulatory drugs commonly cause peripheral nervous system toxicity. Prompt recognition and evaluation of this neurological adverse event by those who provide care to patients with cancer can prove to have a positive impact on the quality of life of those patients.

scholarly journals Real-life versus package insert: A post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers

Vaccine ◽  
2011 ◽  
Vol 29 (31) ◽  
pp. 5000-5006 ◽  
Author(s):  
Christoph Hatz ◽  
Bernhard Beck ◽  
Robert Steffen ◽  
Blaise Genton ◽  
Valérie d’Acremont ◽  
...  
Keyword(s):  
Adverse Event ◽  
Hepatitis A ◽  
Real Life ◽  
Package Insert ◽  
Post Marketing ◽  
Event Rates

Neurological adverse event profile of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor

2018 ◽  
Vol 33 (5) ◽  
pp. 843-847 ◽  
Author(s):  
Paul S. Fishman ◽  
W. Jeffrey Elias ◽  
Pejman Ghanouni ◽  
Ryder Gwinn ◽  
Nir Lipsman ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Adverse Event ◽  
Magnetic Resonance ◽  
Essential Tremor ◽  
Focused Ultrasound ◽  
Resonance Imaging ◽  
Adverse Event Profile ◽  
Neurological Adverse Event

Application of solid-phase immune electron microscopy to study physical and stability characteristics of enterically transmitted non-a, non-b hepatitis virus

1988 ◽  
Vol 46 ◽  
pp. 80-81
Author(s):  
Charles D. Humphrey ◽  
E. H. Cook ◽  
Karen A. McCaustland ◽  
Daniel W. Bradley
Keyword(s):  
Electron Microscopy ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Solid Phase ◽  
Etiologic Agent ◽  
World Health ◽  
Health Concern ◽  
Morphological Identification ◽  
Immune Electron Microscopy

Enterically transmitted non-A, non-B hepatitis (ET-NANBH) is a type of hepatitis which is increasingly becoming a significant world health concern. As with hepatitis A virus (HAV), spread is by the fecal-oral mode of transmission. Until recently, the etiologic agent had not been isolated and identified. We have succeeded in the isolation and preliminary characterization of this virus and demonstrating that this agent can cause hepatic disease and seroconversion in experimental primates. Our characterization of this virus was facilitated by immune (IEM) and solid phase immune electron microscopic (SPIEM) methodologies.Many immune electron microscopy methodologies have been used for morphological identification and characterization of viruses. We have previously reported a highly effective solid phase immune electron microscopy procedure which facilitated identification of hepatitis A virus (HAV) in crude cell culture extracts. More recently we have reported utilization of the method for identification of an etiologic agent responsible for (ET-NANBH).

Sign in / Sign up

Export Citation Format

Share Document